Transcat (TRNS) Competitors

$70.25 +2.39 (+3.53%)

As of 03:54 PM Eastern

TRNS vs. TXG, ALMR, ALNT, EYPT, and FEIM

Should you buy Transcat stock or one of its competitors? MarketBeat compares Transcat with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Transcat include 10x Genomics (TXG), Alamar Biosciences (ALMR), Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Transcat compare to 10x Genomics?

Transcat (NASDAQ:TRNS) and 10x Genomics (NASDAQ:TXG) are both measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, 10x Genomics had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for 10x Genomics and 2 mentions for Transcat. 10x Genomics' average media sentiment score of 0.19 beat Transcat's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Transcat shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Transcat has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.37	$14.52M	$0.85	83.08
10x Genomics	$638.78M	4.90	-$43.54M	-$0.17	N/A

Transcat has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

Transcat currently has a consensus price target of $105.33, indicating a potential upside of 49.16%. 10x Genomics has a consensus price target of $23.17, indicating a potential downside of 6.04%. Given Transcat's stronger consensus rating and higher possible upside, equities research analysts plainly believe Transcat is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Transcat has a net margin of 2.47% compared to 10x Genomics' net margin of -3.55%. Transcat's return on equity of 6.15% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
10x Genomics	-3.55%	-2.86%	-2.23%

Summary

Transcat beats 10x Genomics on 10 of the 17 factors compared between the two stocks.

How does Transcat compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Alamar Biosciences presently has a consensus price target of $30.00, suggesting a potential upside of 37.68%. Transcat has a consensus price target of $105.33, suggesting a potential upside of 49.16%. Given Transcat's higher probable upside, analysts plainly believe Transcat is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Alamar Biosciences had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Transcat. Alamar Biosciences' average media sentiment score of 0.65 beat Transcat's score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Transcat has higher revenue and earnings than Alamar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$87.16M	17.33	N/A	N/A	N/A
Transcat	$278.42M	2.37	$14.52M	$0.85	83.08

Transcat has a net margin of 2.47% compared to Alamar Biosciences' net margin of 0.00%. Transcat's return on equity of 6.15% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Transcat	2.47%	6.15%	4.15%

98.3% of Transcat shares are owned by institutional investors. 2.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Transcat beats Alamar Biosciences on 8 of the 13 factors compared between the two stocks.

How does Transcat compare to Allient?

Transcat (NASDAQ:TRNS) and Allient (NASDAQ:ALNT) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Transcat presently has a consensus target price of $105.33, suggesting a potential upside of 49.16%. Allient has a consensus target price of $72.25, suggesting a potential upside of 13.98%. Given Transcat's stronger consensus rating and higher possible upside, analysts clearly believe Transcat is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Allient had 1 more articles in the media than Transcat. MarketBeat recorded 3 mentions for Allient and 2 mentions for Transcat. Allient's average media sentiment score of 0.27 beat Transcat's score of 0.00 indicating that Allient is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allient	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Transcat shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 2.8% of Transcat shares are held by insiders. Comparatively, 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.37	$14.52M	$0.85	83.08
Allient	$554.48M	1.94	$22.03M	$1.43	44.33

Allient has a net margin of 4.25% compared to Transcat's net margin of 2.47%. Allient's return on equity of 12.47% beat Transcat's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
Allient	4.25%	12.47%	6.37%

Transcat has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Allient has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Summary

Allient beats Transcat on 11 of the 17 factors compared between the two stocks.

How does Transcat compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Transcat has a net margin of 2.47% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Transcat's return on equity of 6.15% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Transcat	2.47%	6.15%	4.15%

Eyepoint Pharmaceuticals presently has a consensus target price of $31.80, suggesting a potential upside of 146.99%. Transcat has a consensus target price of $105.33, suggesting a potential upside of 49.16%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	34.41	-$231.96M	-$3.50	N/A
Transcat	$278.42M	2.37	$14.52M	$0.85	83.08

Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Transcat has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.10 beat Transcat's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eyepoint Pharmaceuticals beats Transcat on 9 of the 16 factors compared between the two stocks.

How does Transcat compare to Frequency Electronics?

Transcat (NASDAQ:TRNS) and Frequency Electronics (NASDAQ:FEIM) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Frequency Electronics has a net margin of 10.78% compared to Transcat's net margin of 2.47%. Frequency Electronics' return on equity of 12.69% beat Transcat's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
Frequency Electronics	10.78%	12.69%	7.84%

Frequency Electronics has lower revenue, but higher earnings than Transcat. Frequency Electronics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.37	$14.52M	$0.85	83.08
Frequency Electronics	$69.81M	8.40	$23.69M	$0.75	79.49

Transcat has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Transcat presently has a consensus target price of $105.33, indicating a potential upside of 49.16%. Frequency Electronics has a consensus target price of $43.67, indicating a potential downside of 26.75%. Given Transcat's higher possible upside, equities analysts clearly believe Transcat is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Frequency Electronics had 2 more articles in the media than Transcat. MarketBeat recorded 4 mentions for Frequency Electronics and 2 mentions for Transcat. Frequency Electronics' average media sentiment score of 0.13 beat Transcat's score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Frequency Electronics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Transcat shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 2.8% of Transcat shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Frequency Electronics beats Transcat on 9 of the 16 factors compared between the two stocks.

Get Transcat News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRNS vs. The Competition

Export

Metric	Transcat	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$655.76M	$2.98B	$38.74B	$12.27B
Dividend Yield	N/A	1.02%	3.22%	5.36%
P/E Ratio	82.69	64.28	168.95	25.45
Price / Sales	2.37	3.52	627.20	73.05
Price / Cash	16.32	25.83	46.59	55.00
Price / Book	2.29	3.94	10.32	7.01
Net Income	$14.52M	$75.72M	$1.06B	$335.03M
7 Day Performance	-8.71%	-2.29%	0.32%	-0.43%
1 Month Performance	-13.48%	5.47%	4.81%	0.99%
1 Year Performance	-21.87%	68.41%	167.90%	34.43%

Transcat Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRNS Transcat	2.4098 of 5 stars	$70.25 +3.5%	$105.33 +49.9%	-28.1%	$651.09M	$278.42M	82.10	1,245	Positive News Upcoming Earnings
TXG 10x Genomics	1.5837 of 5 stars	$21.38 +0.8%	$23.17 +8.4%	+164.1%	$2.69B	$642.82M	N/A	1,240	Analyst Downgrade
ALMR Alamar Biosciences	4.7999 of 5 stars	$20.86 -3.2%	$30.00 +43.8%	N/A	$1.45B	$87.16M	N/A	222
ALNT Allient	3.8137 of 5 stars	$60.24 -1.8%	$72.25 +19.9%	+99.0%	$1.04B	$560.59M	42.61	2,478
EYPT Eyepoint Pharmaceuticals	2.7145 of 5 stars	$11.63 -0.6%	$31.80 +173.4%	+101.3%	$975.32M	$7.61M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRNS) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Transcat (TRNS) Competitors

TRNS vs. TXG, ALMR, ALNT, EYPT, and FEIM

How does Transcat compare to 10x Genomics?

Summary

How does Transcat compare to Alamar Biosciences?

Summary

How does Transcat compare to Allient?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Summary

How does Transcat compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Transcat (TRNS) Competitors

TRNS vs. TXG, ALMR, ALNT, EYPT, and FEIM

How does Transcat compare to 10x Genomics?

Does the media refer more to TRNS or TXG?

Do institutionals and insiders believe in TRNS or TXG?

Which has better valuation & earnings, TRNS or TXG?

Which has more risk & volatility, TRNS or TXG?

Do analysts rate TRNS or TXG?

Is TRNS or TXG more profitable?

Summary

How does Transcat compare to Alamar Biosciences?

Do analysts recommend ALMR or TRNS?

Does the media prefer ALMR or TRNS?

Which has preferable valuation & earnings, ALMR or TRNS?

Is ALMR or TRNS more profitable?

Do insiders and institutionals hold more shares of ALMR or TRNS?

Summary

How does Transcat compare to Allient?

Do analysts prefer TRNS or ALNT?

Does the media refer more to TRNS or ALNT?

Do institutionals and insiders believe in TRNS or ALNT?

Which has preferable valuation & earnings, TRNS or ALNT?

Is TRNS or ALNT more profitable?

Which has more volatility & risk, TRNS or ALNT?

Summary

How does Transcat compare to Eyepoint Pharmaceuticals?

Do institutionals and insiders hold more shares of EYPT or TRNS?

Is EYPT or TRNS more profitable?

Do analysts recommend EYPT or TRNS?

Which has higher earnings & valuation, EYPT or TRNS?

Which has more volatility and risk, EYPT or TRNS?

Does the media favor EYPT or TRNS?

Summary

How does Transcat compare to Frequency Electronics?

Is TRNS or FEIM more profitable?

Which has better earnings and valuation, TRNS or FEIM?

Which has more volatility & risk, TRNS or FEIM?

Do analysts rate TRNS or FEIM?

Does the media favor TRNS or FEIM?

Do institutionals and insiders believe in TRNS or FEIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRNS vs. The Competition

Transcat Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools